Angiomax
- Generic Name: bivalirudin
- Brand Name: Angiomax
Angiomax (Bivalirudin) side effects drug center
Angiomax Side Effects Center
What Is Angiomax?
Angiomax (bivalirudin) is a reversible direct thrombin inhibitor used to prevent blood clots in people with severe chest pain or other conditions undergoing a procedure called angioplasty (to open blocked arteries).
What Are Side Effects of Angiomax?
Common side effects of Angiomax include:
- pain in the back or pelvis,
- nausea,
- vomiting,
- stomach pain or upset,
- restlessness,
- nervousness,
- anxiety,
- headache,
- fever,
- sleep problems (insomnia), or
- pain/bleeding/irritation where the injection was given.
Dosage for Angiomax
The recommended dose of Angiomax is an intravenous (IV) bolus dose of 0.75 mg/kg, followed by an infusion of 1.75 mg/kg/h for the duration of the PCI/PTCA procedure. Five min. after the bolus dose has been administered, an activated clotting time (ACT) should be performed and an additional bolus of 0.3 mg/kg should be given if needed.
What Drugs, Substances, or Supplements Interact with Angiomax?
Angiomax may interact with blood thinners, or other medications used to prevent blood clots. Tell your doctor all medications and supplements you use.
Angiomax During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant before taking Angiomax. Aspirin is usually given with this drug, and aspirin can cause bleeding when it is taken during the last 3 months of pregnancy. Aspirin can also cause side effects in a newborn. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Additional Information
Our Angiomax (bivalirudin) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Angiomax Consumer Information
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have:
- a light-headed feeling, like you might pass out;
- easy bruising or bleeding (nosebleeds, bleeding gums, heavy menstrual bleeding);
- bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
- sudden numbness or weakness, problems with vision or speech;
- urine that looks red, pink, or brown;
- swelling or redness in an arm or leg; or
- bleeding from wounds or needle injections, any bleeding that will not stop.
Bleeding is the most common side effect of bivalirudin.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Angiomax (Bivalirudin)
Angiomax Professional Information
SIDE EFFECTS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In the BAT trials, 79 of the 2161 (3.7%) patients undergoing PCI for treatment of unstable angina and randomized to Angiomax experienced major bleeding events which consisted of: intracranial bleeding, retroperitoneal bleeding, and clinically overt bleeding with a decrease in hemoglobin >3 g/dL or leading to a transfusion of >2 units of blood.
Immunogenicity
As with all peptides, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Angiomax in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.
In in vitro studies, Angiomax exhibited no platelet aggregation response against sera from patients with a history of HIT/HITTS.
Among 494 subjects who received Angiomax in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests. Neither subject demonstrated clinical evidence of allergic or anaphylactic reactions and repeat testing was not performed. Nine additional patients who had initial positive tests were negative on repeat testing.
Postmarketing Experience
Because postmarketing adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions have been identified during post approval use of Angiomax: fatal bleeding; hypersensitivity and allergic reactions including reports of anaphylaxis; lack of anticoagulant effect; thrombus formation during PCI with and without intracoronary brachytherapy, including reports of fatal outcomes; pulmonary hemorrhage; cardiac tamponade; and INR increased.
Read the entire FDA prescribing information for Angiomax (Bivalirudin)
IMAGES
See Images
© Angiomax Patient Information is supplied by Cerner Multum, Inc. and Angiomax Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.